BioVaxys Technology Corp. to Present at Emerging Growth Conference
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF), a clinical-stage company developing a portfolio of vaccines, has announced its participation in the Emerging Growth Conference. The live, interactive online event will provide an opportunity for investors and analysts to engage with BioVaxys’ leadership.
The presentation is scheduled for Thursday, January 16, 2025, from 3:25 PM to 3:35 PM Eastern Time. Attendees can interact with James Passin, CEO, and Kenneth Kovan, President & Chief Operating Officer. The session will include a presentation followed by a Q&A.
To submit questions in advance, or during the event, please email [email protected].
To register for the conference and receive updates, please visit: https://goto.webcasts.com/starthere.jsp?ei=1677199&tp_key=1991879e88&sti=bvaxf
An archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel after the event.
About the Emerging Growth Conference
The Emerging Growth Conference provides public companies with a platform to present and communicate announcements to the investment community. The conference focuses on growth sectors, and highlights companies with strong management teams, innovative products and services, and potential for long-term growth. The audience includes individual and institutional investors, investment advisors, and analysts.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com) is a clinical-stage biopharmaceutical company. The company develops novel immunotherapies based on its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform. These platforms are designed to treat cancers, infectious diseases, antigen desensitization for food allergies, and other immunological diseases.
The Company’s clinical stage pipeline includes maveropepimut-S (MVP-S), in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen.
BioVaxys is also developing:
- DPX™+SurMAGE, a dual-targeted immunotherapy.
- DPX™-RSV for Respiratory Syncytial Virus.
- DPX+rPA for peanut allergy prophylaxis.
- BVX-0918, a personalized immunotherapeutic vaccine.
BioVaxys common shares are listed on the CSE under the stock symbol ‘BIOV’, trade on the Frankfurt Bourse (FRA: 5LB), and in the US (OTCQB: BVAXF).
For more information, visit www.biovaxys.com and connect on X and LinkedIn.
ON BEHALF OF THE BOARDSigned
“James Passin”
James Passin, Chief Executive Officer
Phone: +1 740 358 0555
Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking statements. Actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Investors are encouraged to read BioVaxys’ continuous disclosure documents and audited annual consolidated financial statements available on SEDAR at www.sedar.com
